Hearing Impairment as a Risk Factor for Dementia in Older Adults

Dementia Clinical Trial

Official title:

Modifiable Risk Factors and Dementia - A Study Examining the Association Between Hearing Impairment in Mid-life and Cognitive Impairment in the HUNT4 70+ Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04284384
• Other study ID #: 181009
• Status: Completed
• Start date: August 19, 2019
• Est. completion date: November 20, 2020

Study information

• Verified date: September 2021
• Source: Norwegian Centre for Ageing and Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This Doctor of Philosophy (PhD) project is part of a larger project on potentially modifiable risk factors for dementia in a life course perspective, with an overarching aim to improve prevention of dementia and thereby potentially relieve patient and caregiver distress and decrease societal load. The present PhD project will concentrate on confirming knowledge of HI as an independent risk factor for dementia and exploring potentially causative factors to explain this relationship.

Description:

Despite a huge increase in the knowledge about disease mechanisms in various types of dementia in recent years, no curative treatment exists at present. Results from research on disease-modifying agents have been disappointing. This has led to an increased interest in other ways to reduce the prevalence of dementia. A recent report estimated that up to one third of dementia cases could be delayed or prevented by interventions directed at the most common risk factors. In the "Lancet commission on dementia prevention, treatment, and care", hearing impairment (HI) was identified as the potentially most important modifiable risk factor. Even though HI is considered an important modifiable risk factor, the evidence regarding the association between HI and dementia risk is still limited.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6952
• Est. completion date: November 20, 2020
• Est. primary completion date: November 20, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Living in designated area

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Deafness
• Dementia
• Hearing Loss

Locations

Country	Name	City	State
Norway	Norwegian National Advisory Unit of Ageing and Health	Tønsberg

Sponsors (6)

Lead Sponsor	Collaborator
Norwegian Centre for Ageing and Health	Norwegian University of Science and Technology, The Nord-Trøndelag Health Study, The Norwegian Institute of Public Health, University College London Hospitals, University of Oslo

Country where clinical trial is conducted

Norway, 

References & Publications (1)

GjØra L, Strand BH, Bergh S, Borza T, Brækhus A, Engedal K, Johannessen A, Kvello-Alme M, Krokstad S, Livingston G, Matthews FE, Myrstad C, Skjellegrind H, Thingstad P, Aakhus E, Aam S, Selbæk G. Current and Future Prevalence Estimates of Mild Cognitive Impairment, Dementia, and Its Subtypes in a Population-Based Sample of People 70 Years and Older in Norway: The HUNT Study. J Alzheimers Dis. 2021;79(3):1213-1226. doi: 10.3233/JAD-201275. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of dementia diagnosis in the HUNT 70+ study	Two clinical and scientific experts will independently set at diagnosis of cognitive impairment or dementia based on all available information applying standard diagnostic criteria Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5).	2017-2019
Primary	Rate of Minimal Cognitive Impairment (MCI) in the HUNT 70+ study	Two clinical and scientific experts will independently set at diagnosis of cognitive impairment or dementia based on all available information applying standard diagnostic criteria DSM-5.	2017-2019
Primary	Rate of cognitive impairment defined as age- and education-adjusted thresholds on cognitive assessments scales	The participants have been assessed with the Montreal Cognitive Assessment scale and the ten-word recall test	2017-2019